Skip to main content
. 2019 Jan 1;9(10):1013. doi: 10.1038/s41419-018-1043-6

Fig. 6. The Akt2 inhibitor enhances the FoxO3a/Bim signaling pathway in lymphocytes and reverses GC resistance.

Fig. 6

a Analysis by western blot of Akt1, p-Akt1 (Ser473), Akt2, and p-Akt2 (Ser474) in CCRF-CEM ALL cells treated with DEX, the Akt isoform inhibitors, or DEX plus the Akt inhibitors. b–d Western blot analysis and relative quantification of FoxO3a/Bim signaling proteins in CCRF-CEM ALL cells treated with DEX, Akt1 inhibitor, Akt2 inhibitor or Akt1/2 inhibitor, or DEX plus Akt1 inhibitor, Akt2 inhibitor or Akt1/2 inhibitor. Bar graphs in b–d represent mean ± SD